Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Landray

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
European Heart Journal|December 18, 2013
Clinical trials: how to get closer to the right answer with less effortMartin Landray
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2006
Which cardiovascular risk factors matter in chronic kidney disease?Colin Baigent, Martin Landray
The New England Journal of Medicine|July 25, 2020
Randomization versus Real-World Evidence. ReplyRory Collins, Louise Bowman, Martin Landray
Current Opinion in Nephrology and Hypertension|October 16, 2004
Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trialsColin Baigent, Martin Landray, Marion Warren
Advances in Biological Regulation|August 1, 2022
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trialLeon Peto, Peter Horby, Martin Landray
Kidney International. Supplement|April 16, 2003
Homocysteine, renal function, and risk of cardiovascular diseaseRobert Clarke, Sarah Lewington, Martin Landray
The New England Journal of Medicine|December 6, 2013
Randomized clinical trials--removing obstaclesChristina Reith, Martin Landray, Robert M Califf
The New England Journal of Medicine|February 14, 2020
The Magic of Randomization versus the Myth of Real-World EvidenceRory Collins, Louise Bowman, Martin Landray, et al.
Lancet (London, England)|July 25, 2021
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' replyPeter Horby, Natalie Staplin, Richard Haynes, et al.
JAMA|August 1, 2020
Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized HarmonyRobert M Califf, Adrian F Hernandez, Martin Landray
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
European Heart Journal|December 18, 2013
Clinical trials: how to get closer to the right answer with less effortMartin Landray
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2006
Which cardiovascular risk factors matter in chronic kidney disease?Colin Baigent, Martin Landray
The New England Journal of Medicine|July 25, 2020
Randomization versus Real-World Evidence. ReplyRory Collins, Louise Bowman, Martin Landray
Current Opinion in Nephrology and Hypertension|October 16, 2004
Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trialsColin Baigent, Martin Landray, Marion Warren
Advances in Biological Regulation|August 1, 2022
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trialLeon Peto, Peter Horby, Martin Landray
Kidney International. Supplement|April 16, 2003
Homocysteine, renal function, and risk of cardiovascular diseaseRobert Clarke, Sarah Lewington, Martin Landray
The New England Journal of Medicine|December 6, 2013
Randomized clinical trials--removing obstaclesChristina Reith, Martin Landray, Robert M Califf
The New England Journal of Medicine|February 14, 2020
The Magic of Randomization versus the Myth of Real-World EvidenceRory Collins, Louise Bowman, Martin Landray, et al.
Lancet (London, England)|July 25, 2021
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' replyPeter Horby, Natalie Staplin, Richard Haynes, et al.
JAMA|August 1, 2020
Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized HarmonyRobert M Califf, Adrian F Hernandez, Martin Landray
Pageof 5